granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
Rheumatology · 2015–2015
2decisions
1medicine
1carried consumer input
6individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| rituximab Remission induction in patients with severe active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) who are contraindicated or… | Mar 2015 | Deferred | 6 individuals |
| rituximab Remission induction in patients with severe, active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) who are contraindicated,… | Nov 2015 | Recommended with restriction | no section in document |
What the PBS pays
$24M in government benefit over 2024–25, across 57,210 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| rituximab | $23.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.